Phenomics company Median Technologies and Japanese contract research organisation (CRO) CMIC Holdings have announced a collaboration to provide more comprehensive clinical trial services and accelerate oncology drug development in Japan, China and East Asia.

The collaboration comes after an audit at Median’s headquarters in France at the end of 2017 and will seek to leverage complementary expertise to help biopharmaceutical companies improve and accelerate oncology drug development. CMIC will be granted access to Median’s imaging technologies and services, while Median’s access to biopharmaceutical sponsors with clinical trials in Asia will be extended.

“The agreement with CMIC, a leading CRO in Asia, is a landmark event for Median Technologies,” Median CCO Nicholas Campbell said. “With our enhanced technology and in-depth expertise in oncology medical image interpretation and management, we complement their offering in a key area of growth. We have been accelerating our expansion in Asia with the opening of our subsidiary in Shanghai and recent key new hires in Japan and China. Our CMIC collaboration strengthens our efforts and extends our footprint for our clinical trial business in the fast-growing Asian market. We look forward to a fruitful partnership.”

“The collaboration with Median will further strengthen CMIC’s oncology trial capabilities,” CMIC managing director Toru Fujieda said. “We believe [this partnership] will allow us to provide more satisfying services to our clients. Through this cooperation, we would like to continue building more partnerships in oncology between our two companies,”

CMIC was the first CRO to open in Japan, starting operations in 1992. Today the company provides support services for the development, manufacturing, sales, and marketing of pharmaceutical products. Median Technologies was founded in 2002, and seeks to improve healthcare through the development of innovative imaging technologies and diagnostic tools to monitor disease.